Lucentis (Ranibizumab) Effect on Wet AMD Fades With Time

CHICAGO — Patients with neovascular (wet) age-related macular degeneration (AMD) who are treated with ranibizumab are at risk for substantial vision loss late in the treatment course. This may be mediated in part by the frequency of the intravitreal injections.

These were the main findings from a long-term follow-up of pivotal trial populations from ranibizumab studies presented here...